Dihexa
Also known as AngIV analogue
Preclinical procognitive/synaptogenic compound acting via HGF/c-Met axis. No long-term human safety data.
Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
No Human Data
No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.
Evidence visual
Dihexa evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
extreme
Regulatory
not approved
WADA
none
FDA
unknown
Route
oral
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Dihexa is an AngIV analogue proposed to be procognitive and synaptogenic via the HGF/c-Met axis. It binds HGF and facilitates c-Met receptor engagement, associated with synaptogenesis in preclinical literature. In vitro potency is reported but long-term human safety is not established. High counterfeit risk in the nootropic peptide market.
Decision path
Where Dihexa fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Dihexa belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Binds HGF and facilitates c-Met receptor engagement; associated with synaptogenesis in preclinical models.
oral, subcutaneous
Preclinical; in vitro potency in molar ranges. No established human dosing.
Preclinical synaptogenesis and cognitive enhancement signals.
Animal cognitive endpoints vary by study design; no clear consumer timeline.
No data.
No long-term human safety data; explicitly flag this gap.
Unknown.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Known Interactions
Experimental nootropic stack with limited human data and unclear downside profile.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Dihexa.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.